MYC-mediated synthetic lethality for treatment of hematological malignancies

Current Cancer Drug Targets

Volumn 15, Issue 1, 2015, Pages 53-70

  Li, Xin ^a   Zhang, Xin A ^b   Xie, Wei ^a   Li, Xiaoqing ^a   Huang, Shiang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

C MYC; Hematological malignancy; Oncogene addiction; Small molecule inhibitor; Synthetic lethality; Targeted therapy; Tumorigenesis

Indexed keywords

3 (2 AMINO 5 BENZOXAZOLYL) 1 ISOPROPYL 1H PYRAZOLO [3, 4 D] PYRIMIDIN 4 AMINE; 5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; 6 (4 CHLOROPHENYL) N ETHYL 8 METHOXY 1 METHYL 4H [1, 2, 4] TRIAZOLO [4, 3 A] [1, 4] BENZODIAZEPINE 4 ACETAMIDE; 7 HYDROXYSTAUROSPORINE; ALISERTIB; AURORA KINASE; BROMODOMAIN INHIBITOR; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE; CYTARABINE; FLAVOPIRIDOL; FLUDARABINE; GEMCITABINE; INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; MYELOID LEUKEMIA FACTOR 1; PF 3814735; PROTEIN KINASE PIM 1; SELUMETINIB; TOZASERTIB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BURKITT LYMPHOMA; CARCINOGENESIS; CHEMOSENSITIVITY; GENE AMPLIFICATION; HEMATOLOGIC MALIGNANCY; HUMAN; LARGE CELL LYMPHOMA; LETHALITY; ONCOGENE C MYC; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; ANIMAL; DRUG EFFECTS; HEMATOLOGIC NEOPLASMS; METABOLISM; MOUSE; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; HEMATOLOGIC NEOPLASMS; HUMANS; MICE; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION;

EID: 84924905559     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009615666150105120055     Document Type: Article

References (127)

1. Dang, C.V. MYC on the path to cancer. Cell, 2012, 149(1), 22-35.
2. Meyer, N.; Penn, L.Z. Reflecting on 25 years with MYC. Nat. Rev. Cancer, 2008, 8(12), 976-990.
3. Dudley, J.P.; Mertz, J.A.; Rajan, L.; Lozano, M.; Broussard, D.R. What retroviruses teach us about the involvement of c-Myc in leukemias and lymphomas. Leukemia, 2002, 16(6), 1086-1098.
4. Hoffman, B.; Amanullah, A.; Shafarenko, M.; Liebermann, D.A. The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene, 2002, 21(21), 3414-3421.
5. Vita, M.; Henriksson, M. The Myc oncoprotein as a therapeutic target for human cancer. Semin. Cancer Biol., 2006, 16(4), 318-330.
6. Arvanitis, C.; Felsher, D.W. Conditional transgenic models define how MYC initiates and maintains tumorigenesis. Semin. Cancer Biol., 2006, 16(4), 313-317.
7. Morton, J.P.; Sansom, O.J. MYC-y mice: from tumour initiation to therapeutic targeting of endogenous MYC. Mol. Oncol., 2013, 7(2), 248-258.
8. Adams, J.M.; Harris, A.W.; Pinkert, C.A.; Corcoran, L.M.; Alexander, W.S.; Cory, S.; Palmiter, R.D.; Brinster, R.L. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature, 1985, 318(6046), 533-538.
9. Harris, A.W.; Pinkert, C.A.; Crawford, M.; Langdon, W.Y.; Brinster, R.L.; Adams, J.M. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J. Exp. Med., 1988, 167(2), 353-371.
10. Stewart, M.; Cameron, E.; Campbell, M.; McFarlane, R.; Toth, S.; Lang, K.; Onions, D.; Neil J.C. Conditional expression and oncogenicity of c-myc linked to a CD2 gene dominant control region. Int. J. Cancer, 1993, 53(6), 1023-1030.
11. Felsher, D.W.; Bishop, J.M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell, 1999, 4(2), 199-207.
12. Marinkovic, D.; Marinkovic, T.; Mahr, B.; Hess, J.; Wirth, T. Reversible lymphomagenesis in conditionally c-MYC expressing mice. Int. J. Cancer, 2004, 110(3), 336-342.
13. Luo, H.; Li, Q.; O'Neal, J.; Kreisel, F.; Le Beau, M.M.; Tomasson, M.H. c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. Blood, 2005, 106(7), 2452-2461.
14. Smith, D.P.; Bath, M.L.; Metcalf, D.; Harris, A.W.; Cory, S. MYC levels govern hematopoietic tumor type and latency in transgenic mice. Blood, 2006, 108(2), 653-661.
15. Iritani, B.M.; Eisenman, R.N. c-Myc enhances protein synthesis and cell size during B lymphocyte development. Proc. Natl. Acad. Sci. USA, 1999, 96(23), 13180-13185.
16. Ruggero, D.; Montanaro, L.; Ma, L.; Xu, W.; Londei, P.; Cordon-Cardo, C.; Pandolfi, P.P. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat. Med., 2004, 10(5), 484-486.
17. Wendel, H.G.; Silva, R.L.; Malina, A.; Mills, J.R.; Zhu, H.; Ueda, T.; Watanabe-Fukunaga, R.; Fukunaga, R.; Teruya-Feldstein, J.; Pelletier, J.; Lowe, S.W. Dissecting eIF4E action in tumorigenesis. Genes Dev., 2007, 21(24), 3232-3237.
18. Wendel, H.G.; De Stanchina, E.; Fridman, J.S.; Malina, A.; Ray, S.; Kogan, S.; Cordon-Cardo, C.; Pelletier, J.; Lowe, S.W. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature, 2004, 428(6980), 332-337.
19. van Lohuizen, M.; Verbeek, S.; Krimpenfort, P.; Domen, J.; Saris, C.; Radaszkiewicz, T.; Berns, A. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell, 1989, 56(4), 673-682.
20. Verbeek, S.; van Lohuizen, M.; van der Valk, M.; Domen, J.; Kraal, G.; Berns, A. Mice bearing the E mu-myc and E mu-pim-1 transgenes develop pre-B-cell leukemia prenatally. Mol. Cell Biol., 1991, 11(2), 1176-1179.
21. Allen, J.D.; Verhoeven, E.; Domen, J.; van der Valk, M.; Berns, A. Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc. Oncogene, 1997, 15(10), 1133-1141.
22. Zhou, P.; Levy, N.B.; Xie, H.; Qian, L.; Lee, C.Y.; Gascoyne, R. D.; Craig, R. W. MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. Blood, 2001, 97(12), 3902-3909.
23. Beverly, L.J.; Varmus, H.E. MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family. Oncogene, 2009, 28(9), 1274-1279.
24. Xiang, Z.; Luo, H.; Payton, J.E.; Cain, J.; Ley, T.J.; Opferman, J. T.; Tomasson, M.H. Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia. J. Clin. Invest., 2010, 120(6), 2109-2118.
25. Brunelle, J.K.; Ryan, J.; Yecies, D.; Opferman, J.T.; Letai, A. MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts. J. Cell. Biol., 2009, 187(3), 429-442.
26. Campbell, K.J.; Bath, M.L.; Turner, M.L.; Vandenberg, C.J.; Bouillet, P.; Metcalf, D.; Scott C.L.; Cory, S. Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance. Blood, 2010, 116(17), 3197-3207.
27. Chesi, M.; Robbiani, D.F.; Sebag, M.; Chng, W.J.; Affer, M.; Tiedemann, R.; Valdez, R.; Palmer, S.E.; Haas, S.S.; Stewart, A.K.; Fonseca, R.; Kremer, R.; Cattoretti, G.; Bergsagel, P.L. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell, 2008, 13(2), 167-180.
28. Dechow, T.; Steidle, S.; Götze, K.S.; Rudelius, M.; Behnke, K.; Pechloff, K.; Kratzat, S.; Bullinger, L.; Fend, F.; Soberon, V.; Mitova, N.; Li, Z.; Thaler, M.; Bauer, J.; Pietschmann, E.; Albers, C.; Grundler, R.; Schmidt-Supprian, M.; Ruland, J.; Peschel, C.; Duyster, J.; Rose-John, S.; Bassermann, F.; Keller, U. GP130 activation induces myeloma and collaborates with MYC. J. Clin. Invest., 2014, 124(12), 5263-5274.
29. Delgado, M.D.; Albajar, M.; Gomez-Casares, M.T.; Batlle, A.; León, J. MYC oncogene in myeloid neoplasias. Clin. Transl. Oncol., 2013, 15(2), 87-94.
30. Delgado, M.D.; León, J. Myc roles in hematopoiesis and leukemia. Genes Cancer, 2010, 1(6), 605-616.
31. Xiao, R.; Cerny J.; Devitt, K.; Dresser K.; Nath, R.; Ramanathan, M.; Rodig, S.J.; Chen, B.J.; Woda, B.A.; Yu, H. MYC protein expression is detected in plasma cell myeloma but not in monoclonal gammopathy of undetermined significance (MGUS). Am. J. Surg. Pathol., 2014, 38(6), 776-783.
32. Klapproth, K.; Wirth, T. Advances in the understanding of MYC-induced lymphomagenesis. Br. J. Haematol., 2010, 149(4), 484-497.
33. Chesi, M.; Bergsagel, P.L. Molecular pathogenesis of multiple myeloma: basic and clinical updates. Int. J. Hematol., 2013, 97(3), 313-323.
34. Chesi, M.; Matthews, G.M.; Garbitt, V.M.; Palmer, S.E.; Shortt, J.; Lefebure, M.; Stewart, A.K.; Johnstone, R.W.; Bergsagel, P.L. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood, 2012, 120(2), 376-385.
35. Matthews, G.M.; Lefebure, M.; Doyle, M.A.; Shortt, J.; Ellul, J.; Chesi, M.; Banks, K.M.; Vidacs, E.; Faulkner, D.; Atadja, P.; Bergsagel, P.L.; Johnstone, R.W. Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma. Cell Death Dis., 2013, 4, e798.
36. Nagy, B.; Lundán, T.; Larramendy, M.L.; Aalto, Y.; Zhu, Y.; Niini, T.; Edgren, H.; Ferrer, A.; Vilpo, J.; Elonen, E.; Vettenranta, K.; Franssila, K.; Knuutila, S. Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma. Br. J. Haematol., 2003, 120(3), 434-441.
37. Tamburini, J.; Green, A.S.; Bardet, V.; Chapuis, N.; Park, S.; Willems, L.; Uzunov, M.; Ifrah, N.; Dreyfus, F.; Lacombe, C.; Mayeux, P.; Bouscary, D. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood, 2009, 114(8), 1618-1627.
38. Beroukhim, R.; Mermel, C.H.; Porter, D.; Wei, G.; Raychaudhuri, S.; Donovan, J.; Barretina, J.; Boehm, J.S.; Dobson, J.; Urashima, M.; Mc Henry, K.T.; Pinchback, R.M.; Ligon, A.H.; Cho, Y.J.; Haery, L.; Greulich, H.; Reich, M.; Winckler, W.; Lawrence, M.S.; Weir, B.A.; Tanaka, K.E.; Chiang, D.Y.; Bass, A.J.; Loo, A.; Hoffman, C.; Prensner, J.; Liefeld, T.; Gao, Q.; Yecies, D.; Signoretti, S.; Maher, E.; Kaye, F.J.; Sasaki, H.; Tepper, J.E.; Fletcher, J.A.; Tabernero, J.; Baselga, J.; Tsao, M.S.; Demichelis, F.; Rubin, M.A.; Janne, P.A.; Daly, M.J.; Nucera, C.; Levine, R.L.; Ebert, B.L.; Gabriel, S.; Rustgi, A.K.; Antonescu, C.R.; Ladanyi, M.; Letai, A.; Garraway, L.A.; Loda, M.; Beer, D.G.; True, L.D.; Okamoto, A.; Pomeroy, S.L.; Singer, S.; Golub, T.R.; Lander, E.S.; Getz, G.; Sellers, W.R.; Meyerson, M. The landscape of somatic copy-number alteration across human cancers. Nature, 2010, 463, (7283), 899-905.
39. den Hollander, J.; Rimpi, S.; Doherty, J.R.; Rudelius, M.; Buck, A.; Hoellein, A.; Kremer, M.; Graf, N.; Scheerer, M.; Hall, M.A.; Goga, A.; von Bubnoff, N.; Duyster, J.; Peschel, C.; Cleveland, J. L.; Nilsson, J.A.; Keller, U. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood, 2010, 116(9), 1498-1505.
40. Höglund, A.; Nilsson, L.M.; Muralidharan, S.V.; Hasvold, L.A.; Merta, P.; Rudelius, M.; Nikolova, V.; Keller, U.; Nilsson, J.A. Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells. Clin. Cancer Res., 2011, 17(22), 7067-7079.
41. Dave, S.S.; Fu, K.; Wright, G.W.; Lam, L.T.; Kluin, P.; Boerma, E.J.; Greiner, T.C.; Weisenburger, D.D.; Rosenwald, A.; Ott, G.; Müller-Hermelink, H.K.; Gascoyne, R.D.; Delabie, J.; Rimsza, L.M.; Braziel, R.M.; Grogan, T.M.; Campo, E.; Jaffe, E.S.; Dave, B.J.; Sanger, W.; Bast, M.; Vose, J.M.; Armitage, J.O.; Connors, J.M.; Smeland, E.B.; Kvaloym S.; Holte, H.; Fisher, R.I.; Miller, T.P.; Montserrat, E.; Wilson, W.H.; Bahl, M.; Zhao, H.; Yang, L.; Powell, J.; Simon, R.; Chan, W.C.; Staudt, L.M. Molecular diagnosis of Burkitt’s lymphoma N. Engl. J. Med., 2006, 354(23), 2431-2442.
42. Alizadeh, A.A.; Eisen, M.B.; Davis, R.E.; Ma, C.; Lossos, I.S.; Rosenwald, A.; Boldrick, J.C.; Sabet, H.; Tran, T.; Yu, X.; Powell, J.I.; Yang, L.; Marti, G.E.; Moore, T.; Hudson, J. Jr.; Lu, L.; Lewis, D.B.; Tibshirani, R.; Sherlock, G.; Chan, W.C.; Greiner, T.C.; Weisenburger, D.D.; Armitage, J.O.; Warnke, R.; Levy, R.; Wilson, W.; Grever, M.R.; Byrd, J.C.; Botstein, D.; Brown, P.O.; Staudt, L.M. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 2000, 403(6769), 503-511.
43. Wright, G.; Tan, B.; Rosenwald, A.; Hurt, E.H.; Wiestner, A.; Staudt, L.M. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc. Natl. Acad. Sci. USA, 2003, 100(17), 9991-9996.
44. Rossi, D.; Berra, E.; Cerri, M.; Deambrogi, C.; Barbieri, C.; Franceschetti, S.; Lunghi, M.; Conconi, A.; Paulli, M.; Matolcsy, A.; Pasqualucci, L.; Capello, D.; Gaidano, G. Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B-cell lymphoma. Haematologica, 2006, 91(10), 1405-1409.
45. Martelli, M.; Ferreri, A.J.; Agostinelli, C.; Di Rocco, A.; Pfreundschuh, M.; Pileri, S.A. Diffuse large B-cell lymphoma. Crit. Rev. Oncol. Hematol., 2013, 87(2), 146-171.
46. Pourdehnad, M.; Truitt, M.L.; Siddiqi, I.N.; Ducker, G.S.; Shokat, K.M.; Ruggero, D. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc. Natl. Acad. Sci. USA, 2013, 110(42), 11988-11993.
47. His, E.D.; Jung, S.H.; Lai, R.; Johnson, J.L.; Cook, J.R.; Jones, D.; Devos, S.; Cheson, B.D.; Damon, L.E.; Said, J. Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk. Lymphoma, 2008, 49(11), 2081-2090.
48. de Vos, S.; Krug, U.; Hofmann, W.K.; Pinkus, G.S.; Swerdlow, S.H.; Wachsman, W.; Grogan, T.M.; Said, J.W.; Koeffler, H.P. Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV. Diagn. Mol. Pathol., 2003, 12(1), 35-43.
49. Zhu, Y.; Hollmén, J.; Räty, R.; Aalto, Y.; Nagy, B.; Elonen, E.; Kere, J.; Mannila, H.; Franssila, K.; Knuutila, S. Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma. Br. J. Haematol., 2002, 119(4), 905-915.
50. Martelli, M.; Ferreri, A.J.; Johnson, P. Primary mediastinal large B-cell lymphoma. Crit. Rev. Oncol. Hematol., 2008, 68(3), 256-263.
51. Müller-Tidow, C.; Steffen, B.; Cauvet, T.; Tickenbrock, L.; Ji, P.; Diederichs, S.; Sargin, B.; Köhler, G.; Stelljes, M.; Puccetti, E.; Ruthardt, M.; deVos, S.; Hiebert, S.W.; Koeffler, H.P.; Berdel, W.E.; Serve, H. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol. Cell. Biol., 2004, 24(7), 2890-2904.
52. Rice, K.L.; Hormaeche, I.; Doulatov, S.; Flatow, J.M.; Grimwade, D.; Mills, K.I.; Leiva, M.; Ablain, J.; Ambardekar, C.; McConnell, M.J.; Dick, J.E.; Licht, J.D. Comprehensive genomic screens identify a role for PLZF-RARalpha as a positive regulator of cell proliferation via direct regulation of c-MYC. Blood, 2009, 114(27), 5499-5511.
53. Soucek, L.; Whitfield, J.; Martins, C.P.; Finch, A.J.; Murphy, D.J.; Sodir, N.M.; Karnezis, A.N.; Swigart, L.B.; Nasi, S.; Evan, G.I. Modelling Myc inhibition as a cancer therapy. Nature, 2008, 455(7213), 679-683.
54. Chappell, J.; Dalton, S. Roles for MYC in the establishment and maintenance of pluripotency. Cold Spring Harb Perspect. Med., 2013, 3(12), a014381.
55. Ott, G.; Rosenwald, A.; Campo, E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Blood, 2013, 122(24), 3884-3891.
56. Hermeking, H. The MYC oncogene as a cancer drug target. Curr. Cancer Drug Targets, 2003, 3(3), 163-175.
57. Prochownik, E.V.; Vogt, P.K. Therapeutic targeting of Myc. Genes Cancer, 2010, 1(6), 650-659.
58. Fletcher, S.; Prochownik, E.V. Small-molecule inhibitors of the Myc oncoprotein. Biochim. Biophys. Acta 2014 Mar 19. pii: S1874-9399(14)00057-1. doi: 10.1016/j.bbagrm.2014.03.005.
59. Yap, T.A.; Sandhu, S.K.; Carden, C.P.; de Bono, J.S. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J. Clin., 2011, 61(1), 31-49.
60. Weidle, U.H.; Maisel, D.; Eick, D. Synthetic lethality-based targets for discovery of new cancer therapeutics. Cancer Genomics Proteomics, 2011, 8(4), 159-171.
61. Wang, Y.; Engels, I.H.; Knee, D.A.; Nasoff, M.; Deveraux, Q.L.; Quon, K.C. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell, 2004, 5(5), 501-512.
62. Malumbres, M.; Barbacid, M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer, 2009, 9(3), 153-166.
63. Alvarez, E.; Northwood, I.C.; Gonzalez, F.A.; Latour, D.A.; Seth, A.; Abate, C.; Curran, T.; Davis, R.J. Pro-Leu-Ser/Thr-Pro is a consensus primary sequence for substrate protein phosphorylation. Characterization of the phosphorylation of c-myc and c-jun proteins by an epidermal growth factor receptor threonine 669 protein kinase. J. Biol. Chem., 1991, 266(23), 15277-15285.
64. Wang, Q.; Wu P.C.; Roberson, R.S.; Luk, B.V.; Ivanova, I.; Chu, E.; Wu, D.Y. Survivin and escaping in therapy-induced cellular senescence. Int. J. Cancer, 2011, 128(7), 1546-1558.
65. Fang Z.H.; Dong, C.L.; Chen, Z.; Zhou, B.; Liu, N.; Lan, H.F.; Liang, L.; Liao, W.B.; Zhang, L.; Han, Z.C. Transcriptional regulation of survivin by c-Myc in BCR/ABL-transformed cells: implications in anti-leukaemic strategy. J. Cell Mol. Med., 2009, 13(8B), 2039-2052.
66. Cosgrave, N.; Hill, A.D.; Young, L.S. Growth factor-dependent regulation of survivin by c-myc in human breast cancer. J. Mol. Endocrinol., 2006, 37(3), 377-390.
67. Goga, A.; Yang, D.; Tward, A.D.; Morgan, D.O.; Bishop, J.M. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat. Med., 2007, 13(7), 820-827.
68. Katayama, H.; Sen, S. Aurora kinase inhibitors as anticancer molecules. Biochim. Biophys. Acta, 2010, 1799(10-12), 829-839.
69. Ruchaud, S.; Carmena, M.; Earnshaw, W.C. Chromosomal passengers: conducting cell division. Nat. Rev. Mol. Cell Biol., 2007, 8(10), 798-812.
70. Sun, H.; Wang, Y.; Wang, Z.; Meng, J.; Qi, Z.; Yang, G. Aurora-A controls cancer cell radio- and chemoresistance via ATM/Chk2-mediated DNA repair networks. Biochim. Biophys. Acta, 2014, 1843(5), 934-944.
71. Wang, Y.; Sun, H.; Wang, Z.; Liu, M.; Qi, Z.; Meng, J.; Sun, J.; Yang, G. Aurora-A: a potential DNA repair modulator. Tumour Biol., 2014, 35 (4), 2831-2836.
72. Yang, S.; He, S.; Zhou, X.; Liu, M.; Zhu, H.; Wang, Y.; Zhang, W.; Yan, S.; Quan, L.; Bai, J.; Xu, N. Suppression of Aurora-A oncogenic potential by c-Myc downregulation. Exp. Mol. Med., 2010, 42(11), 759-767.
73. Harrington, E.A.; Bebbington, D.; Moore, J.; Rasmussen, R.K.; Ajose-Adeogun, A.O.; Nakayama, T.; Graham, J.A.; Demur, C.; Hercend, T.; Diu-Hercend, A.; Su, M.; Golec J.M.; Miller, K.M. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med., 2004, 10(3), 262-267.
74. Huang, X.F.; Luo, S.K.; Xu, J.; Li, J.; Xu, D.R.; Wang, L.H.; Yan, M.; Wang, X.R.; Wan, X.B.; Zheng, F.M.; Zeng, Y.X.; Liu, Q. Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia. Blood 2008, 111(5), 2854-2865.
75. Yang, D.; Liu, H.; Goga, A.; Kim, S.; Yuneva, M.; Bishop, J.M. Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc. Natl. Acad. Sci. USA, 2010, 107(31), 13836-13841.
76. Medema, R.H.; Macůrek, L. Checkpoint control and cancer. Oncogene, 2012, 31(21), 2601-2613.
77. Rohban, S.; Campaner, S. Myc induced replicative stress response: How to cope with it and exploit it. Biochim. Biophys. Acta, 2014 Apr 13. pii: S1874-9399(14)00085-6. doi: 10.1016/j.bbagrm.2014. 04.008.
78. Murga, M.; Campaner, S.; Lopez-Contreras, A.J.; Toledo, L.I.; Soria, R.; Montaña, M.F.; D'Artista, L.; Schleker, T.; Guerra, C.; Garcia, E.; Barbacid, M.; Hidalgo, M.; Amati, B.; Fernandez-Capetillo, O. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat. Struct. Mol. Biol., 2011, 18(12), 1331-1335.
79. Ferrao, P.T.; Bukczynska, E.P.; Johnstone, R.W.; McArthur, G.A. Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells. Oncogene, 2012, 31(13), 1661-1672.
80. Nawijn, M.C.; Alendar, A.; Berns, A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat. Rev. Cancer, 2011, 11(1), 23-34.
81. Zhang, Y.; Wang, Z.; Li, X.; Magnuson, N.S. Pim kinase-dependent inhibition of c-Myc degradation. Oncogene, 2008, 27(35), 4809-4819.
82. Zippo, A.; De Robertis, A.; Serafini, R.; Oliviero, S. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat. Cell. Biol., 2007, 9(8), 932-944.
83. Brault, L.; Gasser, C.; Bracher, F.; Huber, K.; Knapp, S.; Schwaller, J. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica, 2010, 95(6),1004-1015.
84. Chen, L.S.; Redkar, S.; Taverna, P.; Cortes, J.E.; Gandhi, V. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukaemia. Blood 2011, 118(3), 693-702.
85. Chen, L.S.; Redkar, S.; Bearss, D.; Wierda, W.G.; Gandhi, V. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukaemia cells. Blood 2009, 114(19), 4150-4157.
86. Yang, Q.; Chen, L.S.; Neelapu, S.S.; Miranda, R.N.; Medeiros, L.J.; Gandhi, V. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma. Blood 2012, 120(17), 3491-3500.
87. Lin, Y.W.; Beharry, Z.M.; Hill, E.G.; Song, J.H.; Wang, W.; Xia, Z.; Zhang, Z.; Aplan, P.D.; Aster, J.C.; Smith, C.D.; Kraft, A.S. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukaemia/lymphoma. Blood, 2010, 115(4), 824-833.
88. Asano, J.; Nakano, A.; Oda, A.; Amou, H.; Hiasa, M.; Takeuchi, K.; Miki, H.; Nakamura, S.; Harada, T.; Fujii, S.; Kagawa, K.; Endo, I.; Yata, K.; Sakai, A. Ozaki, S.; Matsumoto, T.; Abe, M. The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells. Leukemia, 2011, 25(7), 1182-1188.
89. Zoncu, R.; Efeyan, A.; Sabatini, D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell. Biol., 2011, 12(1), 21-35.
90. Shortt, J.; Johnstone, R.W. Oncogenes in cell survival and cell death. Cold Spring Harb Perspect. Biol., 2012, 4(12), a009829.
91. Zhang, F.; Beharry, Z.M.; Harris, T.E.; Lilly, M.B.; Smith, C.D.; Mahajan, S.; Kraft, A.S. PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells. Cancer Biol. Ther., 2009, 8(9), 846-853.
92. Lin, C.J.; Nasr, Z.; Premsrirut, P.K.; Porco, J.A. Jr.; Hippo, Y.; Lowe, S.W.; Pelletier, J. Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis. Cell Rep., 2012, 1(4), 325-333.
93. Lin, C.J.; Cencic, R.; Mills, J.R.; Robert, F.; Pelletier, J. c-Myc and eIF4F are components of a feedforward loop that links transcription and translation. Cancer Res., 2008, 68(13), 5326-5334.
94. Perciavalle, R.M.; Opferman, J.T. Delving deeper: MCL-1's contributions to normal and cancer biology. Trends Cell. Biol., 2013, 23(1), 22-29.
95. Glaser, S.P.; Lee, E.F.; Trounson, E.; Bouillet, P.; Wei, A.; Fairlie, W.D.; Izon, D.J.; Zuber, J.; Rappaport, A.R.; Herold, M.J.; Alexander, W.S.; Lowe, S.W.; Robb, L.; Strasser, A. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev., 2012, 26(2), 120-125.
96. Zhang, B.; Gojo, I.; Fenton, R.G. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood, 2002, 99(6), 1885-1893.
97. Kelly, G.L.; Grabow, S.; Glaser S.P.; Fitzsimmons L.; Aubrey, B.J.; Okamoto, T.; Valente, L.J.; Robati, M.; Tai, L.; Fairlie, W.D.; Lee, E.F.; Lindstrom, M.S.; Wiman, K.G.; Huang, D.C.; Bouillet, P.; Rowe, M.; Rickinson, A.B.; Herold, M.J.; Strasser, A. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev., 2014, 28(1), 58-70.
98. Canavese, M.; Santo, L.; Raje, N. Cyclin dependent kinases in cancer: potential for therapeutic intervention. Cancer Biol. Ther., 2012, 13(7), 451-457.
99. Bhalla, S.; Evens, A.M.; Dai, B.; Prachand, S.; Gordon, L.I.; Gartenhaus, R.B. The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma. Blood, 2011, 118(4), 1052-1061.
100. Wu, S.Y.; Chiang, C.M. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J. Biol. Chem., 2007, 282(18), 13141-13145.
101. Stower, H. Gene expression: super enhancers. Nat. Rev. Genet., 2013, 14(6), 367.
102. Hnisz, D.; Abraham, B.J.; Lee, T.I.; Lau, A.; Saint-André, V.; Sigova, A.A.; Hoke, H.A.; Young, R.A. Super-enhancers in the control of cell identity and disease. Cell, 2013, 155(4), 934-947.
103. Whyte, W.A.; Orlando, D.A.; Hnisz, D.; Abraham, B.J.; Lin, C.Y.; Kagey, M.H.; Rahl P.B.; Lee T.I.; Young, R.A. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell, 2013, 153(2), 307-319.
104. Affer, M.; Chesi, M.; Chen, W.D.; Keats, J.J.; Demchenko, Y.N.; Tamizhmani, K.; Garbitt, V.M.; Riggs, D.L.; Brents, L.A.; Roschke, A.V.; Van Wier, S.; Fonseca, R.; Bergsagel, P.L.; Kuehl W.M. Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia, 2014, 28(8), 1725-1735.
105. Lovén, J.; Hoke, H.A.; Lin, C.Y.; Lau, A.; Orlando, D.A.; Vakoc, C.R.; Bradner, J.E.; Lee, T.I.; Young, R.A. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell, 2013, 153(2), 320-334.
106. Chapuy, B.; McKeown, M.R.; Lin, C.Y.; Monti, S.; Roemer, M.G.; Qi, J.; Rahl, P.B.; Sun, H.H.; Yeda, K.T.; Doench, J.G.; Reichert, E.; Kung, A.L.; Rodig, S.J.; Young, R.A.; Shipp, M.A.; Bradner, J.E. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell, 2013, 24(6), 777-790.
107. Filippakopoulos, P.; Qi, J.; Picaud, S.; Shen, Y.; Smith, W.B.; Fedorov, O.; Morse, E.M.; Keates, T.; Hickman, T.T.; Felletar, I.; Philpott, M.; Munro, S.; McKeown, M.R.; Wang, Y.; Christie, A.L.; West, N.; Cameron, M.J.; Schwartz, B.; Heightman, T.D.; La Thangue, N.; French, C.A.; Wiest, O.; Kung A.L.; Knapp, S.; Bradner, J.E. Selective inhibition of BET bromodomains. Nature, 2010, 468(7327), 1067-1073.
108. Zuber, J.; Shi, J.; Wang, E.; Rappaport, A.R.; Herrmann, H.; Sison, E.A.; Magoon, D.; Qi, J.; Blatt, K.; Wunderlich, M.; Taylor, M.J.; Johns, C.; Chicas, A.; Mulloy, J.C.; Kogan, S.C.; Brown, P.; Valent, P.; Bradner, J.E.; Lowe, S.W.; Vakoc, C.R. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature, 2011, 478(7370), 524-528.
109. Herrmann, H.; Blatt, K.; Shi, J.; Gleixner, K.V.; Cerny-Reiterer, S.; Müllauer, L.; Vakoc, C.R.; Sperr, W.R.; Horny, H.P.; Bradner, J.E.; Zuber, J.; Valent, P. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. Oncotarget, 2012, 3(12), 1588-1599.
110. Roderick, J.E.; Tesell, J.; Shultz, L.D.; Brehm, M.A.; Greiner, D.L.; Harris, M.H.; Silverman, L.B.; Sallan, S.E.; Gutierrez, A.; Look, A.T.; Qi, J.; Bradner, J.E.; Kelliher, M.A. c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood, 2014, 123(7), 1040-1050.
111. Mertz, J.A.; Conery, A.R.; Bryant, B.M.; Sandy, P.; Balasubramanian, S.; Mele, D.A.; Bergeron, L.; Sims, R.J. 3rd. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad Sci. USA, 2011, 108(40), 16669-16674.
112. Ott, C.J.; Kopp, N.; Bird, L.; Paranal, R.M.; Qi, J.; Bowman, T.; Rodig, S.J.; Kung, A.L.; Bradner, J.E.; Weinstock, D.M. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood, 2012, 120(14), 2843-2852.
113. Da Costa, D.; Agathanggelou, A.; Perry, T.; Weston, V.; Petermann, E.; Zlatanou, A.; Oldreive, C.; Wei, W.; Stewart, G.; Longman, J.; Smith, E.; Kearns, P.; Knapp, S.; Stankovic, T. BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia. Blood Cancer J., 2013, 3, e126.
114. Chaidos, A.; Caputo, V.; Gouvedenou, K.; Liu, B.; Marigo, I.; Chaudhry, M.S.; Rotolo, A.; Tough, D.F.; Smithers, N.N.; Bassil, A.K.; Chapman, T.D.; Harker, N.R.; Barbash, O.; Tummino, P.; Al-Mahdi, N.; Haynes, A.C.; Cutler, L.; Le, B.; Rahemtulla, A.; Roberts, I.; Kleijnen, M.; Witherington, J.J.; Parr, N.J.; Prinjha, R.K.; Karadimitris, A. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood, 2014, 123(5), 697-705.
115. Delmore, J.E.; Issa, G.C.; Lemieux, M.E.; Rahl, P.B.; Shi, J.; Jacobs, H.M.; Kastritis, E.; Gilpatrick, T.; Paranal, R.M.; Qi, J.; Chesi, M.; Schinzel, A.C.; McKeown, M.R.; Heffernan, T.P.; Vakoc, C.R.; Bergsagel, P.L.; Ghobrial, I.M.; Richardson, P.G.; Young, R.A.; Hahn, W.C.; Anderson, K.C.; Kung, A.L.; Bradner, J.E.; Mitsiades, C.S. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell, 2011, 146(6), 904-917.
116. Shaffer, A.L.; Emre, N.C.; Lamy, L.; Ngo, V.N.; Wright, G.; Xiao, W.; Powell, J.; Dave, S.; Yu, X.; Zhao, H.; Zeng, Y.; Chen, B.; Epstein, J.; Staudt, L.M. IRF4 addiction in multiple myeloma. Nature, 2008, 454(7201), 226-231.
117. Shortt, J.; Hsu, A.K.; Martin, B.P.; Doggett, K.; Matthews, G.M.; Doyle, M.A.; Ellul, J.; Jockel, T.E.; Andrews, D.M.; Hogg, S.J.; Reitsma, A.; Faulkner, D.; Bergsagel, P.L.; Chesi, M.; Heath, J.K.; Denny, W.A.; Thompson, P.E.; Neeson, P.J.; Ritchie, D.S.; McArthur, G.A.; Johnstone, R.W. The drug vehicle and solvent N-methylpyrrolidone is an immunomodulator and antimyeloma compound. Cell Rep., 2014, 7(4), 1009-1019.
118. Bordeleau, M.E.; Robert, F.; Gerard, B.; Lindqvist, L.; Chen, S. M.; Wendel, H.G.; Brem, B.; Greger, H.; Lowe, S.W.; Porco, J.A. Jr.; Pelletier, J. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J. Clin. Invest., 2008, 118(7), 2651-2660.
119. Cencic, R.; Hall, D.R.; Robert, F.; Du, Y.; Min, J.; Li, L.; Qui, M.; Lewis, I.; Kurtkaya, S.; Dingledine, R.; Fu, H.; Kozakov, D.; Vajda, S.; Pelletier, J. Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. Proc. Natl. Acad. Sci. USA, 2011, 108(3), 1046-1051.
120. Fox, C.J.; Hammerman, P.S.; Cinalli, R.M.; Master, S.R.; Chodosh, L.A.; Thompson, C.B. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev., 2003, 17(15), 1841-1854.
121. Schatz, J.H.; Oricchio, E.; Wolfe, A.L.; Jiang, M.; Linkov, I.; Maragulia, J.; Shi, W.; Zhang, Z.; Rajasekhar, V.K.; Pagano, N.C.; Porco, J.A. Jr; Teruya-Feldstein, J.; Rosen, N.; Zelenetz, A.D.; Pelletier, J.; Wendel, H.G. Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. J. Exp. Med., 2011, 208(9), 1799-1807.
122. Karp, J.E.; Smith, B.D.; Resar, L.S.; Greer, J.M.; Blackford, A.; Zhao, M.; Moton-Nelson, D.; Alino, K.; Levis, M.J.; Gore, S.D.; Joseph, B.; Carraway, H.; McDevitt, M.A.; Bagain, L.; Mackey, K.; Briel, J.; Doyle, L.A.; Wright, J.J.; Rudek, M.A. Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood, 2011, 117(12), 3302-3310.
123. Alvarado, Y.; Giles, F.J.; Swords, R.T. The PIM kinases in hematological cancers. Expert Rev. Hematol., 2012, 5(1), 81-96.
124. Maugeri-Saccà, M.; Bartucci, M.; De Maria, R. Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy. Cancer Treat. Rev., 2013, 39(5), 525-533.
125. Quinn, B.A.; Dash, R.; Azab, B.; Sarkar, S.; Das, S.K.; Kumar, S.; Oyesanya, R.A.; Dasgupta, S.; Dent, P.; Grant, S.; Rahmani, M.; Curiel, D.T.; Dmitriev, I.; Hedvat, M.; Wei, J.; Wu, B.; Stebbins, J.L.; Reed, J.C.; Pellecchia, M.; Sarkar, D.; Fisher, P.B. Targeting Mcl-1 for the therapy of cancer. Expert Opin. Investig. Drugs, 2011, 20(10), 1397-1411.
126. Narlik-Grassow, M.; Blanco-Aparicio, C.; Carnero, A. The PIM family of serine/threonine kinases in cancer. Med. Res. Rev., 2014, 34(1), 136-159.
127. Malina, A.; Mills, J.R.; Pelletier, J. Emerging therapeutics targeting mRNA translation. Cold Spring Harb Perspect. Biol., 2012, 4(4), a012377.